Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABPNYSE:IBIONYSE:NKGNNASDAQ:SONN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABPAbpro$0.22-7.0%$0.24$0.15▼$13.00$13.07M-0.035.82 million shs2.01 million shsIBIOiBio$0.93-9.9%$0.92$0.64▼$6.89$15.33M0.96437,425 shs352,822 shsNKGNNKGen Biotech$0.33-2.2%$0.22$0.10▼$1.39$14.83M1.21.57 million shs25,934 shsSONNSonnet BioTherapeutics$1.15-2.5%$1.26$1.08▼$14.80$3.64M0.94383,362 shs21,702 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABPAbpro-8.97%+8.95%+12.83%-51.71%+23,129,900.00%IBIOiBio+7.22%+11.17%+28.75%-79.72%-59.92%NKGNNKGen Biotech+0.15%+0.75%+12.50%+98.76%-73.84%SONNSonnet BioTherapeutics+0.85%+2.16%-8.53%-13.55%-34.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABPAbproN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBio1.127 of 5 stars3.50.00.00.00.00.00.6NKGNNKGen Biotech0.8178 of 5 stars0.05.00.00.00.62.50.0SONNSonnet BioTherapeutics2.8225 of 5 stars3.55.00.00.02.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABPAbpro 3.00Buy$4.001,760.47% UpsideIBIOiBio 3.00Buy$4.30363.31% UpsideNKGNNKGen Biotech 0.00N/AN/AN/ASONNSonnet BioTherapeutics 3.00Buy$20.001,639.13% UpsideCurrent Analyst Ratings BreakdownLatest SONN, NKGN, IBIO, and ABP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/7/2025SONNSonnet BioTherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/28/2025SONNSonnet BioTherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABPAbpro$183K71.42N/AN/AN/A∞IBIOiBio$375K40.88N/AN/A$1.41 per share0.66NKGNNKGen Biotech$80K185.41N/AN/A($2.68) per share-0.12SONNSonnet BioTherapeutics$1M3.64N/AN/A$1.32 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABPAbproN/AN/A0.00∞N/AN/AN/AN/AN/AIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/ANKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/ASONNSonnet BioTherapeutics-$7.44MN/A0.00∞N/AN/A-408.93%-174.13%8/13/2025 (Estimated)Latest SONN, NKGN, IBIO, and ABP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/AABPAbproN/A-$0.08N/A-$0.08N/AN/A5/13/2025Q2 2025SONNSonnet BioTherapeutics-$0.92-$0.89+$0.03-$0.89N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABPAbproN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/ASONNSonnet BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABPAbproN/AN/AN/AIBIOiBio0.051.761.76NKGNNKGen BiotechN/A0.020.02SONNSonnet BioTherapeuticsN/A2.152.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABPAbpro23.30%IBIOiBio7.90%NKGNNKGen Biotech76.17%SONNSonnet BioTherapeutics9.45%Insider OwnershipCompanyInsider OwnershipABPAbpro20.80%IBIOiBio0.58%NKGNNKGen Biotech10.36%SONNSonnet BioTherapeutics2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABPAbpro1560.79 million4.57 millionN/AIBIOiBio10016.52 million9.82 millionN/ANKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionableSONNSonnet BioTherapeutics103.17 million3.01 millionNot OptionableSONN, NKGN, IBIO, and ABP HeadlinesRecent News About These CompaniesFinancial Comparison: Madrigal Pharmaceuticals (NASDAQ:MDGL) & Sonnet BioTherapeutics (NASDAQ:SONN)June 12 at 1:29 AM | americanbankingnews.comsonnet biotherapeutics receives nasdaq delisting noticeJune 4, 2025 | investing.comSonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development SummitMay 1, 2025 | globenewswire.comSonnet Releases Virtual Investor "What This Means" SegmentApril 16, 2025 | globenewswire.comAir Traffic Controllers Lost Contact With Doomed Pilot Shortly After Takeoff: NTSBApril 11, 2025 | franklinreporter.comSonnet BioTherapeutics reports positive results from ovarian cancer therapy trialApril 7, 2025 | msn.comSonnet BioTherapeutics Reports Positive Phase 1b/2a Data For SON-1010April 6, 2025 | nasdaq.comSonnet BioTherapeutics advances in cancer trialApril 6, 2025 | uk.investing.comSonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at ...April 6, 2025 | seekingalpha.comSonnet Biotherapeutics Holdings Inc trading halted, news pendingApril 4, 2025 | markets.businessinsider.comSonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab comboApril 4, 2025 | markets.businessinsider.comSonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest DoseApril 4, 2025 | globenewswire.comSonnet BioTherapeutics appoints interim CEO and new presidentApril 3, 2025 | investing.comSonnet BioTherapeutics Names Raghu Rao Interim CEO As Founder PassesApril 3, 2025 | nasdaq.comPilot Killed In NJ Crash Was CEO Of Cancer-Focused Biotech CompanyApril 3, 2025 | msn.comDeadly plane crash in NJ neighborhood sounds like bomb explosionApril 2, 2025 | nj1015.comLawrenceville Man Piloted Plane That Crashed In Six Mile Run; Flight Lasted 5 MinutesApril 2, 2025 | franklinreporter.comPilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech CompanyApril 2, 2025 | msn.comSonnet BioTherapeutics announces passing of founder, CEO Pankaj MohanApril 2, 2025 | markets.businessinsider.comSonnet Announces Release of Corporate Update VideoApril 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSONN, NKGN, IBIO, and ABP Company DescriptionsAbpro NASDAQ:ABP$0.22 -0.02 (-7.05%) As of 04:00 PM EasternAbpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.iBio NYSE:IBIO$0.93 -0.10 (-9.89%) Closing price 04:00 PM EasternExtended Trading$0.94 +0.01 (+1.07%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.NKGen Biotech NYSE:NKGN$0.33 -0.01 (-2.22%) As of 03:32 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Sonnet BioTherapeutics NASDAQ:SONN$1.15 -0.03 (-2.54%) Closing price 03:59 PM EasternExtended Trading$1.17 +0.02 (+1.74%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
